(43 days)
The Diamondback 360°™ Orbital Atherectomy System is a percutaneous orbital atherectomy system indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and who are acceptable candidates for percutaneous transluminal atherectomy.
The Diamondback 360°™ Orbital Atherectomy System is also indicated for removal of stenotic material from artificial arteriovenous dialysis fistulae (A-V grafts).
The Diamondback 360°™ Orbital Atherectomy System (OAS) is intended for use in the treatment of peripheral artery and A-V graft stenosis.
OAS provides a method of removing stenotic material from peripheral arteries and A-V grafts. OAS applies a diamond coated, eccentrically rotating cutting surface to ablate stenotic material. The resulting particles of removed stenotic material are very small and can be absorbed by the body.
The Diamondback 360° Orbital Atherectomy System consists of the following three significant components:
- Orbital atherectomy device,
- Orbital atherectomy controller, and
- Atherectomy guidewire.
This 510(k) is for the same device with modifications to the crown assembly of the orbital atherectomy device for a more consistent design and performance.
The provided text is a 510(k) summary for a medical device called the Diamondback 360°™ Orbital Atherectomy System. It describes the device, its intended use, and technology, and states that laboratory test data was provided to support the safety of a modification to the device. However, this document does not contain information about acceptance criteria, detailed device performance, a study proving the device meets acceptance criteria, sample sizes, ground truth establishment, expert qualifications, adjudication methods, or MRMC studies.
The document primarily focuses on establishing substantial equivalence to previously cleared predicate devices (K071350 and K071427) based on modifications to the crown assembly for "a more consistent design and performance." The conclusion states, "Laboratory test data were provided to support the safety of the modification to the Diamondback 360°TM Orbital Atherectomy System. No new questions of safety or effectiveness are raised." This implies that the testing performed was likely focused on technical aspects related to the modification rather than a clinical performance study with predefined acceptance criteria as typically seen for AI/ML device evaluations.
Therefore, I cannot provide the requested information from the given text. The provided text is a regulatory submission for a medical device modification, not a study report detailing performance metrics against specific acceptance criteria.
{0}------------------------------------------------
Section. 5 510(k) Summary
| Company Name: | Cardiovascular Systems, Inc.651 Campus DriveSt. Paul, MN 55112 | ||
|---|---|---|---|
| Contact: | Robert ThatcherExecutive Vice President | NOV 0 9 2007 | |
| Phone: | (651) 259-1630 | ||
| Fax: | (651) 259-1696 | ||
| Summary Date: | Sept 26, 2007 | ||
| Trade Name: | Diamondback 360°™ Orbital Atherectomy System | ||
| Common Name: | Peripheral Atherectomy Device | ||
| Classification Name: | Peripheral Atherectomy Catheter (21 CFR 870.4875; Product Code:MCW) | ||
| Predicate Device: | 510(k) Number:Manufacture:Trade Name: | K071350Cardiovascular Systems, Inc. | Diamondback 360°™ Orbital Atherectomy System |
| 510(k) Number:Manufacture:Trade Name: | K071427Cardiovascular Systems, Inc. | Diamondback 360°™ Orbital Atherectomy System |
Description of Device 5.1
The Diamondback 360°™ Orbital Atherectomy System (OAS) is intended for use in the treatment of peripheral artery and A-V graft stenosis.
OAS provides a method of removing stenotic material from peripheral arteries and A-V grafts. OAS applies a diamond coated, eccentrically rotating cutting surface to ablate stenotic material. The resulting particles of removed stenotic material are very small and can be absorbed by the body.
The Diamondback 360° Orbital Atherectomy System consists of the following three significant components:
- Orbital atherectomy device,
{1}------------------------------------------------
-
- Orbital atherectomy controller, and
-
- Atherectomy guidewire.
This 510(k) is for the same device with modifications to the crown assembly of the orbital atherectomy device for a more consistent design and performance.
5.2 Intended Use
The Diamondback 360°™ Orbital Atherectomy System is a percutaneous orbital atherectomy system indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and who are acceptable candidates for percutaneous transluminal atherectomy.
The Diamondback 360°TM Orbital Atherectomy System is also indicated for removal of stenotic material from artificial arteriovenous dialysis fistulae (A-V grafts).
5.3 Technology
The Diamondback 360°TM Orbital Atherectorny System provides a method of removing occlusive atherosclerotic or stenotic material. The OAS applies a diamond coated, eccentrically rotating cutting surface to ablate stenotic tissue. The resulting particles of removed stenotic tissue are very small and can be absorbed by the body. This same technology was cleared to market for use in peripheral arteries in 510(k) K071350 and for use in A-V grafts in 510(k) K071427.
5.4 Conclusions
The Diamondback 360°TM Orbital Atherectomy System is substantially equivalent to the predicate devices. Laboratory test data were provided to support the safety of the modification to the Diamondback 360°TM Orbital Atherectomy System. No new questions of safety or effectiveness are raised.
{2}------------------------------------------------
Image /page/2/Picture/2 description: The image shows the seal of the Department of Health & Human Services USA. The seal features an eagle-like symbol with three stylized human profiles facing right, overlaid with three curved lines. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the symbol.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
NOV 0 9 2007
Cardiovascular Systems, Inc. c/o Mr. John Carline Regulatory Consultant Libra Medical, LLC 18555 37th Ave. N Plymouth, MN 55446
Re: K072748 Diamondback 360° Orbital Atherectomy System Regulation Number: 21 CFR 870.4875 Regulation Name: Intraluminal artery stripper Regulatory Class: II (Two) Product Code: MCW Dated: October 30, 2007 Received: October 31, 2007
Dear Mr. Carline:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{3}------------------------------------------------
Page 2 - Mr. John Carline
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Dma R. Wachner
W Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Indications For Use Statement Section. 4
510(k) Number: KO722748
Device Name: Diamondback 360° Orbital Atherectomy System
Indications for Use:
The Diamondback 360°™ Orbital Atherectomy System is a percutaneous orbital atherectomy system indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and who are acceptable candidates for percutaneous transluminal atherectomy.
The Diamondback 360°™ Orbital Atherectomy System is also indicated for removal of stenotic material from artificial arteriovenous dialysis fistulae (A-V grafts).
Prescription Use X (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
Concurrence of CDRH, Office of Device Evaluation (ODE)
una R. Vachner
(Division Sign-Off) (Division Sign-On)
Division of Cardiovascular Devices
510(k) Number K072748
Cardiovascular Systems, Inc.
Diamondback 360°™ OAS
§ 870.4875 Intraluminal artery stripper.
(a)
Identification. An intraluminal artery stripper is a device used to perform an endarterectomy (removal of plaque deposits from arterisclerotic arteries.)(b)
Classification. Class II (performance standards).